Afatinib

證據等級: L5

預測適應症: 10 個

Afatinib: From EGFR-Mutated Non-Small Cell Lung Cancer to HER2-Positive Breast Carcinoma

One-Sentence Summary

Afatinib is an irreversible pan-HER (ErbB) tyrosine kinase inhibitor originally approved for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The TxGNN model predicts it may be effective for HER2 Positive Breast Carcinoma, with 10 clinical trials and 19 publications currently supporting this direction, yielding a prediction confidence of 98.65% and an evidence level of L1.

Quick Overview

Item	Content
Original Indication	EGFR mutation-positive non-small cell lung cancer (based on EMA/FDA global approval; no Danish national authorisation on file)
Predicted New Indication	HER2 Positive Breast Carcinoma
TxGNN Prediction Score	98.65%
Evidence Level	L1
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Afatinib is an orally administered small molecule that irreversibly blocks the entire ErbB (HER) receptor family — specifically EGFR (HER1), HER2, and HER4 — by forming covalent bonds with the ATP-binding domain of these kinases. This permanently silences downstream pro-tumour signalling cascades (e.g., MAPK, PI3K/AKT). This mechanism distinguishes afatinib from first-generation reversible EGFR inhibitors such as gefitinib and erlotinib, providing more sustained and broader receptor blockade.

HER2-positive breast carcinoma is defined by HER2 gene amplification and/or protein overexpression, which occurs in approximately 15–20% of all breast cancers and historically confers a poor prognosis. Because HER2 is a primary and direct molecular target of afatinib, the mechanistic alignment between drug and disease is exceptionally strong (★★★★★). Both HER2-positive breast cancer and EGFR-mutated NSCLC share fundamental dependence on the HER/ErbB receptor signalling network, providing a compelling and well-characterised biological rationale for repurposing.

The dedicated LUX-Breast clinical programme — spanning Phase 1 through Phase 3 — was designed precisely to evaluate afatinib in HER2-positive breast cancer. The pivotal LUX-Breast 1 Phase 3 trial (NCT01125566; n=508) compared afatinib plus vinorelbine against the trastuzumab-based standard of care in trastuzumab-pre-treated patients; although the primary progression-free survival (PFS) endpoint narrowly missed statistical significance, the programme generated a comprehensive safety database and identified subgroups — particularly patients with brain metastases and those treated with dual HER2 blockade strategies — that may benefit from further targeted investigation. Afatinib’s established CNS penetration adds biological plausibility for these niche but high-unmet-need populations.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01125566	Phase 3	Completed	508	LUX-Breast 1: Afatinib + vinorelbine vs. trastuzumab + vinorelbine in HER2-overexpressing metastatic breast cancer after one prior trastuzumab treatment. Primary PFS endpoint not statistically significant; comprehensive safety and subgroup data available — highest-grade direct evidence for this indication.
NCT01441596	Phase 2	Completed	121	LUX-Breast 3: Randomised, afatinib ± vinorelbine vs. investigator’s choice in HER2+ breast cancer with progressive brain metastases after trastuzumab and/or lapatinib. Multi-arm efficacy and safety data in a high-unmet-need subpopulation.
NCT01594177	Phase 2	Completed	65	Neoadjuvant dual HER2 blockade: afatinib + trastuzumab added to anthracycline/taxane chemotherapy in locally advanced or operable HER2+ breast cancer. Pathological complete response (pCR) rates evaluated; supports dual-blockade concept.
NCT00431067	Phase 2	Completed	41	Afatinib monotherapy in HER2+ metastatic breast cancer after failure of trastuzumab-containing regimens. Established foundational single-agent activity data in trastuzumab-refractory patients.
NCT02438722	Phase 2/3	Active, not recruiting	174	Randomised trial of afatinib + cetuximab vs. afatinib alone in treatment-naïve EGFR mutation-positive NSCLC. Explores dual ErbB blockade strategy; full results pending — design highly relevant to combination approaches.
NCT00826267	Phase 2	Completed	29	Randomised neoadjuvant three-arm study: afatinib vs. trastuzumab vs. lapatinib in HER2-positive Stage IIIa locally advanced breast cancer (treatment-naïve). Provides direct head-to-head comparative data.
NCT04158947	Phase 2	Unknown	130	Afatinib + T-DM1 vs. T-DM1 alone in HER2+ breast cancer with active refractory brain metastases. Phase I dose-finding followed by Phase II efficacy assessment; biologically plausible given afatinib’s CNS penetration. Status unknown reduces confidence.
NCT01320280	Phase 2	Terminated	29	Afatinib in HER2-positive hormone-refractory prostate cancer after docetaxel failure. Early termination limits efficacy interpretation; safety profile in HER2+ solid tumours remains informative.
NCT01531764	Phase 2	Terminated	2	Afatinib + vinorelbine in intermediate HER2 expression (IHC 2+/FISH-negative) metastatic breast cancer. Terminated after enrolling only 2 patients; no meaningful efficacy conclusions possible.
NCT00950742	Phase 1	Completed	18	Maximum tolerated dose (MTD) determination of afatinib in combination with trastuzumab in HER2-positive advanced breast cancer. Preliminary tolerability and pharmacokinetic data only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35138529	2022	Clinical Trial Report	Breast Cancer Res Treat	LUX-Breast 2: Afatinib alone and in combination with vinorelbine or paclitaxel in HER2+ metastatic breast cancer patients who failed prior trastuzumab/lapatinib. Evaluated a sequential monotherapy-then-combination strategy; real-world efficacy and safety data.
35653982	2022	Systematic Review / Network Meta-analysis	ESMO Open	Systematic review and network meta-analysis of TKI-containing regimens (including afatinib) for HER2+ breast cancer brain metastases. Compared clinical outcomes against non-TKI regimens across multiple trials.
24080156	2014	Systematic Review	Cancer Treatment Reviews	Systematic review of dual HER2-targeting strategies in HER2+ breast cancer, including afatinib combinations. Synthesises evidence on trastuzumab resistance mechanisms and rationale for pan-ErbB blockade.
29772459	2018	Review	Cancer Treatment Reviews	Comprehensive review of TKIs for brain metastases in HER2+ breast cancer. Discusses CNS penetration properties, including afatinib’s documented blood-brain barrier activity, and clinical evidence across agents.
29604436	2018	Review	Pharmacological Research	Review of investigational chemotherapy and novel pharmacokinetic mechanisms for breast cancer brain metastases, including second-generation pan-HER inhibitors such as afatinib.
33122343	2021	In vitro / Mechanistic Study	Clin Cancer Res	Evaluated effects of HER-family TKIs (afatinib, lapatinib, neratinib) on antibody-dependent cell-mediated cytotoxicity (ADCC) in combination with trastuzumab and pertuzumab in HER2-expressing breast cancer cells. Provides mechanistic insight into combination synergy.
38367127	2024	Comparative Study	Clin Exp Metastasis	Comparison of T-DM1, T-DXd, and disitamab vedotin in a multi-resistant HER2+ breast cancer lung metastasis model. Provides context for the evolving resistance landscape and therapeutic sequencing relevant to afatinib’s positioning.
30350178	2018	Phase I Clinical Study	Cancer Chemother Pharmacol	Phase I trial of afatinib + 3-weekly trastuzumab with optimised anti-diarrhoeal management in HER2+ metastatic cancer. Safety, tolerability, and pharmacokinetics of the combination; supports feasibility of combination dosing.
33894300	2021	Review	BBA Reviews on Cancer	Review of HER2-targeted therapies across cancer types (breast, gastric). Contextualises afatinib’s mechanism within the broader HER2-targeted treatment landscape, including resistance pathways.
24870559	2014	Review	Expert Opin Investig Drugs	Expert review on afatinib specifically in breast cancer treatment. Evaluates its promise as a trastuzumab-resistance strategy, summarises early LUX-Breast clinical data, and compares afatinib with neratinib.

Denmark Market Information

Afatinib is currently not marketed in Denmark. No marketing authorisations are registered in the Danish Medicines Agency (Lægemiddelstyrelsen) database, and no centralised EMA authorisations are reflected in the local registry for this product (data cutoff: 2026-04-04).

Practical note for clinical teams: Afatinib (Giotrif®) holds a centralised EMA marketing authorisation for first-line treatment of adults with EGFR mutation-positive locally advanced or metastatic NSCLC. As an EMA-authorised product, it is legally available across all EU member states, including Denmark, but distribution and active marketing in Denmark appear limited. Access for unlicensed indications (e.g., HER2+ breast cancer) would require either a named-patient programme, compassionate use application, or participation in a clinical trial. Consult the hospital pharmacy for current availability and reimbursement status.

Cytotoxicity

Afatinib is an antineoplastic agent targeting ErbB/HER receptors in cancer cells. It is classified as a targeted therapy, not conventional cytotoxic chemotherapy.

Item	Content
Cytotoxicity Classification	Targeted therapy — irreversible covalent pan-ErbB (HER1/HER2/HER4) tyrosine kinase inhibitor (second-generation)
Myelosuppression Risk	Low — afatinib is not a classical myelosuppressive agent; significant haematological toxicity is uncommon compared to cytotoxic chemotherapy
Emetogenicity Classification	Low — oral targeted agents in this class carry minimal emetogenic potential
Monitoring Items	Liver function tests (ALT, AST, bilirubin); renal function and electrolytes (particularly magnesium, potassium); left ventricular ejection fraction (LVEF) if used in combination with trastuzumab; dermatological assessment (acneiform rash, paronychia, skin fissures); diarrhoea grading (Common Terminology Criteria); pulmonary function (interstitial lung disease surveillance)
Handling Protection	Standard oral anticancer agent handling precautions apply — follow institutional cytotoxic handling policy for oral antineoplastic drugs; no intravenous preparation required

Safety Considerations

Structured safety data (key warnings, contraindications, drug-drug interactions) were not available in this evidence pack. Please refer to the approved Summary of Product Characteristics (SmPC) for Giotrif® for complete safety information, including but not limited to: interstitial lung disease, hepatotoxicity, diarrhoea management, embryo-foetal toxicity, and keratitis.

For drug-drug interaction screening, consult the current Giotrif® SmPC and institutional pharmacy resources. Of note, afatinib is a substrate and inhibitor of P-glycoprotein (P-gp); interactions with P-gp inducers (e.g., rifampicin) and inhibitors (e.g., ritonavir, ciclosporin) are clinically relevant and should be reviewed for each patient.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Afatinib has strong mechanistic alignment with HER2-positive breast carcinoma as an irreversible pan-HER inhibitor directly targeting the disease’s primary driver. The completed LUX-Breast Phase 3 programme (LUX-Breast 1; n=508), multiple completed Phase 2 trials, and a substantive supporting literature base collectively provide L1-level evidence. Although the primary PFS endpoint in LUX-Breast 1 was not statistically significant versus trastuzumab, clinically meaningful activity in subpopulations — particularly patients with brain metastases and those receiving dual HER2-blockade regimens — warrants structured further evaluation.

To proceed, the following is needed:

Safety profile completion: Retrieve the full EMA-approved SmPC for Giotrif® to document key warnings, contraindications, and drug interactions (Data Gap DG001)
Mechanism of action documentation: Complete DrugBank API query for afatinib to formally document MOA (Data Gap DG002)
Danish access pathway: Confirm availability via named-patient programme or compassionate use in consultation with the hospital pharmacy and Lægemiddelstyrelsen, given the absence of an active Danish marketing authorisation for breast cancer
Subpopulation definition: Specify the target patient group most likely to benefit — e.g., trastuzumab-refractory HER2+ metastatic breast cancer, or HER2+ patients with active brain metastases — before any clinical protocol is drafted
LUX-Breast 1 subgroup analysis: Review published subgroup data to identify responder characteristics and inform patient selection criteria for any investigator-initiated study
Cardiac monitoring plan: Establish a structured LVEF monitoring protocol, particularly if afatinib is to be used in combination with trastuzumab or other cardiotoxic agents
Regulatory classification review: Determine whether a repurposing application to the EMA or a Danish regulatory notification is required given the existing NSCLC authorisation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.